The second batch of medical insurance key monitoring list is here!

Medical Network, March 31.
On March 30, the Fujian Provincial Medical Insurance Bureau announced the second batch of medical insurance key monitoring drugs and a list of key drugs.
The second batch of key monitoring drugs involves ten varieties, with as many as 59 key drugs.
Since Fujian Province has clearly strengthened the management of key monitoring drugs for medical insurance, two batches of lists have been issued one after another.
According to the requirements, the medical insurance key monitoring drug list and the key drug list are subject to dynamic management, which is adjusted every six months in principle.

 

3 The two batches of key monitoring lists of drugs are listed

 

In terms of quantity, the second batch of Fujian medical insurance key monitoring list is consistent with the first batch, all of which are 10 varieties, involving 1 foreign company and 9 domestic companies .
Including AstraZeneca's Omeprazole Sodium for Injection, Shiyao's Butylphthalide Soft Capsules, etc.

 

According to the "Notice on Strengthening the Management of Key Medical Insurance Monitoring Drugs" issued by the Fujian Provincial Medical Insurance Bureau, key monitored drugs mainly refer to: drugs with an average monthly shipment value of more than 5 million yuan; drugs with an average monthly shipment value ranking the top 20; Drugs with an average monthly shipment value of more than 2 million and a month-on-month increase of more than 30%.
Or drugs that are not necessary for disease treatment, have insufficient clinical efficacy evidence, are not recommended by authoritative disease diagnosis and treatment guidelines or are not included in the clinical path form, do not have pharmacoeconomic advantages, and are found to have sales through performance monitoring, medical insurance audit supervision, and reporting complaints.
Use abnormal medicines.

 

In accordance with the regulations of Fujian Province, for drugs included in the key monitoring list, a "yellow" mark is marked on the province's joint pharmnet.
com.
cn/news/yyzb/" target="_blank">procurement platform for pharmaceutical equipment .
If there is an abnormal situation in the procurement and use, the Provincial Pharmaceutical and Equipment Joint Procurement Center and the medical insurance departments at all levels shall notify the production and distribution enterprises to make an explanation, and conduct an interview to supervise the rectification.
Provide early warning notifications of abnormal usage to medical institutions with a high percentage of usage.
If the monthly shipment amount exceeds 5 million yuan, the manufacturer shall be instructed to lower the online price according to regulations from the following month, and adjust the maximum sales price limit and medical insurance payment standards accordingly .
Production and distribution enterprises that fail to rectify or refuse to rectify the drug purchases included in the key monitoring list are subject to suspension of payment for related drugs, suspension of online connection, and cancellation of online connection, depending on the situation.

 

　　Under the strengthening of the supervision and management of key monitored drugs, the effects of related drug control are more obvious.
Compare the list of the first batch of medical insurance key monitored drugs issued by Fujian in mid-2020, Southwest Pharmaceutical's ceftizoxime sodium for injection, and Liaoning Haisco's methanesulfonic acid Seven drugs including dolasetron injection and Beijing Bonte’s leuprolide acetate sustained-release microspheres for injection have been transferred out of the first batch of key monitoring lists, and then included in the second batch of key monitoring lists.

 

　　However, AstraZeneca’s omeprazole sodium for injection (40mg, 1 bottle/box; 40mg intravenous drip, 1 bottle/bottle), Shuanghe Pharmaceutical (Hainan)’s lansoprazole for injection (30mg, 10 Branches/boxes), Chongqing Yaoyou Pharmaceutical’s Adenosylcobalamin for Injection (1.
5mg 10pcs/box), the three first batch of key monitored varieties are still on the second batch of key monitoring list.

 

　　24 medicines removed from the list of key concerns

 

　　For the list of key medicines issued by Fujian Province, compared with the 44 in the first batch, the number in the second batch is more, reaching 59.
Among them, 30 domestic medicines and 29 imported medicines are involved.

 

　　Fujian emphasized that it will strengthen the supervision and management of key drugs.
For the drugs included in the list of key concerns, the "blue" logo will be marked on the province's joint procurement platform for pharmaceutical equipment.
If there is an abnormal increase in procurement, the Provincial Pharmaceutical Procurement Center shall notify the relevant production enterprise to make an explanation.
And to strengthen the attention to the audit of the drugs on the key concern list , and promptly remind the relevant doctors or medical institutions if there are signs of unreasonable use.
For the drugs included in the list of key concerns, if there are abnormal purchases and use situations and the rectification is not effective, they should be adjusted and included in the list of key monitoring drugs in a timely manner.

 

　　It is worth noting that, except for the drugs that were included in the first batch of key monitoring and key attention lists, other drugs are no longer subject to key monitoring and key attention.

 

　　According to incomplete statistics, a total of 24 drugs were removed from the list of key drugs, including Pfizer's cefoperazone sodium and sulbactam sodium for injection, Sanofi's insulin glargine injection, and Roche's bevacizumab injection.
These varieties are not lack of some medicines that are included in the national procurement.

 

　　Focus on monitoring drugs or focus on centralized procurement

 

　　After the announcement of the first batch of national key-monitored drugs for rational use in 2019, provinces (municipalities) have successively announced the first batch of key-monitored product catalogs.
Most areas have directly followed the national version of the catalog, some areas have added or decreased, and some areas have also introduced various measures to restrict the use of key monitored varieties.

 

　　In recent years, the sales of the first batch of key monitoring products included in the national edition have declined significantly.
According to data from Mi Nei.
com, 52 chemical drugs in the national key surveillance catalogue showed a cliff-like decline under the impact of the epidemic.
In the first half of 2020, the sales of public medical institutions in China dropped by 67.
10% compared with the first half of 2019.
Its sales proportion has also dropped from 4.
0% in the first half of 2019 to 1.
5% in the first half of 2020.

 

　　Insiders said that the drugs included in the key monitoring and key concern list are likely to become the key covered varieties of provincial-level mass procurement.
At the same time, in accordance with the requirements of the National Medical Insurance Bureau, drugs that are included in the national key monitoring scope should be transferred out of the payment scope first.
Superimposed on the management measures of key monitored varieties in various places, the varieties included in key monitoring may face multiple pressures from limited quantities, price reductions, or even falling out of the market.

　　Medical Network, March 31.
On March 30, the Fujian Provincial Medical Insurance Bureau announced the second batch of medical insurance key monitoring drugs and a list of key drugs.
The second batch of key monitoring drugs involves ten varieties, with as many as 59 key drugs.
Since Fujian Province has clearly strengthened the management of key monitoring drugs for medical insurance, two batches of lists have been issued one after another.
According to the requirements, the medical insurance key monitoring drug list and the key drug list are subject to dynamic management, which is adjusted every six months in principle.

 

　　3 The two batches of key monitoring lists of drugs are listed

 

　　In terms of quantity, the second batch of Fujian medical insurance key monitoring list is consistent with the first batch, all of which are 10 varieties, involving 1 foreign company and 9 domestic companies .
Including AstraZeneca's Omeprazole Sodium for Injection, Shiyao's Butylphthalide Soft Capsules, etc.

 

　　According to the "Notice on Strengthening the Management of Key Medical Insurance Monitoring Drugs" issued by the Fujian Provincial Medical Insurance Bureau, key monitored drugs mainly refer to: drugs with an average monthly shipment value of more than 5 million yuan; drugs with an average monthly shipment value ranking the top 20; Drugs with an average monthly shipment value of more than 2 million and a month-on-month increase of more than 30%.
Or drugs that are not necessary for disease treatment, have insufficient clinical efficacy evidence, are not recommended by authoritative disease diagnosis and treatment guidelines or are not included in the clinical path form, do not have pharmacoeconomic advantages, and are found to have sales through performance monitoring, medical insurance audit supervision, and reporting complaints.
Use abnormal medicines.

 

　　In accordance with the regulations of Fujian Province, for drugs included in the key monitoring list, a "yellow" mark is marked on the province's joint pharmnet.
com.
cn/news/yyzb/" target="_blank">procurement platform for pharmaceutical equipment .
If there is an abnormal situation in the procurement and use, the Provincial Pharmaceutical and Equipment Joint Procurement Center and the medical insurance departments at all levels shall notify the production and distribution enterprises to make an explanation, and conduct an interview to supervise the rectification.
Provide early warning notifications of abnormal usage to medical institutions with a high percentage of usage.
If the monthly shipment amount exceeds 5 million yuan, the manufacturer shall be instructed to lower the online price according to regulations from the following month, and adjust the maximum sales price limit and medical insurance payment standards accordingly .
Production and distribution enterprises that fail to rectify or refuse to rectify the drug purchases included in the key monitoring list are subject to suspension of payment for related drugs, suspension of online connection, and cancellation of online connection, depending on the situation.

 

　　Under the strengthening of the supervision and management of key monitored drugs, the effects of related drug control are more obvious.
Compare the list of the first batch of medical insurance key monitored drugs issued by Fujian in mid-2020, Southwest Pharmaceutical's ceftizoxime sodium for injection, and Liaoning Haisco's methanesulfonic acid Seven drugs including dolasetron injection and Beijing Bonte’s leuprolide acetate sustained-release microspheres for injection have been transferred out of the first batch of key monitoring lists, and then included in the second batch of key monitoring lists.

 

　　However, AstraZeneca’s omeprazole sodium for injection (40mg, 1 bottle/box; 40mg intravenous drip, 1 bottle/bottle), Shuanghe Pharmaceutical (Hainan)’s lansoprazole for injection (30mg, 10 Branches/boxes), Chongqing Yaoyou Pharmaceutical’s Adenosylcobalamin for Injection (1.
5mg 10pcs/box), the three first batch of key monitored varieties are still on the second batch of key monitoring list.

 

　　24 medicines removed from the list of key concerns

 

　　For the list of key medicines issued by Fujian Province, compared with the 44 in the first batch, the number in the second batch is more, reaching 59.
Among them, 30 domestic medicines and 29 imported medicines are involved.

 

　　Fujian emphasized that it will strengthen the supervision and management of key drugs.
For the drugs included in the list of key concerns, the "blue" logo will be marked on the province's joint procurement platform for pharmaceutical equipment.
If there is an abnormal increase in procurement, the Provincial Pharmaceutical Procurement Center shall notify the relevant production enterprise to make an explanation.
And to strengthen the attention to the audit of the drugs on the key concern list , and promptly remind the relevant doctors or medical institutions if there are signs of unreasonable use.
For the drugs included in the list of key concerns, if there are abnormal purchases and use situations and the rectification is not effective, they should be adjusted and included in the list of key monitoring drugs in a timely manner.

 

　　It is worth noting that, except for the drugs that were included in the first batch of key monitoring and key attention lists, other drugs are no longer subject to key monitoring and key attention.

 

　　According to incomplete statistics, a total of 24 drugs were removed from the list of key drugs, including Pfizer's cefoperazone sodium and sulbactam sodium for injection, Sanofi's insulin glargine injection, and Roche's bevacizumab injection.
These varieties are not lack of some medicines that are included in the national procurement.

 

　　Focus on monitoring drugs or focus on centralized procurement

 

　　After the announcement of the first batch of national key-monitored drugs for rational use in 2019, provinces (municipalities) have successively announced the first batch of key-monitored product catalogs.
Most areas have directly followed the national version of the catalog, some areas have added or decreased, and some areas have also introduced various measures to restrict the use of key monitored varieties.

 

　　In recent years, the sales of the first batch of key monitoring products included in the national edition have declined significantly.
According to data from Mi Nei.
com, 52 chemical drugs in the national key surveillance catalogue showed a cliff-like decline under the impact of the epidemic.
In the first half of 2020, the sales of public medical institutions in China dropped by 67.
10% compared with the first half of 2019.
Its sales proportion has also dropped from 4.
0% in the first half of 2019 to 1.
5% in the first half of 2020.

 

　　Insiders said that the drugs included in the key monitoring and key concern list are likely to become the key covered varieties of provincial-level mass procurement.
At the same time, in accordance with the requirements of the National Medical Insurance Bureau, drugs that are included in the national key monitoring scope should be transferred out of the payment scope first.
Superimposed on the management measures of key monitored varieties in various places, the varieties included in key monitoring may face multiple pressures from limited quantities, price reductions, or even falling out of the market.